FY2024 Earnings Forecast for CRVS Issued By HC Wainwright

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for Corvus Pharmaceuticals in a report issued on Thursday, January 2nd. HC Wainwright analyst S. Lee expects that the company will earn ($0.41) per share for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at $0.14 EPS.

A number of other brokerages have also recently issued reports on CRVS. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. LADENBURG THALM/SH SH upped their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, Oppenheimer lifted their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ CRVS opened at $5.75 on Monday. The stock has a market capitalization of $369.48 million, a PE ratio of -6.18 and a beta of 1.07. Corvus Pharmaceuticals has a one year low of $1.30 and a one year high of $10.00. The business’s fifty day moving average price is $7.62 and its 200-day moving average price is $5.36.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Several hedge funds have recently bought and sold shares of CRVS. Nwam LLC purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter worth approximately $53,000. XTX Topco Ltd bought a new position in shares of Corvus Pharmaceuticals in the third quarter worth $74,000. Virtu Financial LLC purchased a new stake in shares of Corvus Pharmaceuticals in the third quarter worth $83,000. Avity Investment Management Inc. boosted its stake in Corvus Pharmaceuticals by 138.2% during the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock valued at $146,000 after buying an additional 16,000 shares during the period. Finally, Oppenheimer & Co. Inc. bought a new stake in Corvus Pharmaceuticals during the third quarter valued at $89,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.